Titre : | The Benzodiazepine Withdrawal Symptom Questionnaire: psychometric evaluation during a discontinuation program in depressed chronic benzodiazepine users in general practice |
Titre traduit : | (Questionnaire sur les symptômes de sevrage des benzodiazépines : évaluation psychométrique dans le cadre d'un programme de désintoxication en médecine générale d'usagers de benzodiazépines en dépression chronique.) |
Auteurs : | COUVEE J. E. ; F. G. ZITMAN |
Type de document : | Périodique |
Année de publication : | 2002 |
Format : | 337-345 / graph. ; tabl. |
Note générale : |
Addiction, 2002, 97, (3), 337-345 |
Langues: | Anglais |
Discipline : | TRA (Traitement et prise en charge / Treatment and care) |
Mots-clés : |
Thésaurus mots-clés BENZODIAZEPINES ; PSYCHOMETRIE ; SYNDROME DE SEVRAGE ; TEST ; EVALUATION ; FIABILITE ; VALIDITE |
Résumé : |
FRANÇAIS : Le BWSQ a été évalué auprès de 230 patients par rapport aux symptômes de sevrage suivants : perturbation sensorielle et de la perception, troubles de l'humeur, douleurs musculaires et perte de mémoire. Ce test montre une bonne fiabilité, et de faibles scores pendant un sevrage sont prédicteurs d'un usage ultérieur moindre de benzodiazépines. ENGLISH : Background: The Benzodiazepine Withdrawal Symptom Questionnaire (BWSO, Tyrer et al. 1990) has been developed to measure distinct features of the benzodiazepine withdrawal syndrome. However, psychometric evaluations of this questionnaire are scarce. Aims, setting: To evaluate the BWSO during a discontinuation program carried out by general practitioners in 230 depressed chronic benzodiazepine users. Findings: Reliability coefficients during the program were between 0.84 and 0.88 and the test-retest correlations were between 0.75 and 0.88 during withdrawal. Mean scores of the BWSO during withdrawal differentiated between completers and failures (p=0.036). The factor structure underlying the items consisted of perceptual and sensory disturbances, dysphoric mood, muscular pain and memory loss. Low scores during the last phase of tapering off predicted no, or limited, use of benzodiazepines in the first years following discontinuation (p=0.003). Conclusions: We found the BWSO to measure symptoms during benzodiazepine withdrawal in a reliable way. Our findings indicate some construct validity for BWSQ. Low scores during withdrawal predict more limited future use of benzodiazepines. (Author' s abstract) |
Note de contenu : | graph. ; tabl. |
Domaine : | Autres substances / Other substances |
Refs biblio. : | 16 |
Affiliation : |
Medical Department GlaxoSmithKline Huis ter Heideweg 62, 3705 LZ Zeist Pays-Bas. Netherlands. |
Numéro Toxibase : | 206063 |
Centre Emetteur : | 02 Coordonnateur |
Exemplaires
Disponibilité |
---|
aucun exemplaire |
Accueil